NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

花生過敏 - 市場洞察,流行病學,市場預測 2028年

Peanut Allergy - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 534808
出版日期 按訂單生產 內容資訊 英文 145 Pages
商品交期: 2-10個工作天內
價格
花生過敏 - 市場洞察,流行病學,市場預測 2028年 Peanut Allergy - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 145 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的花生過敏2018年患病數推算為869萬3,872人,市場規模31億4,480萬美元。美國擁有最大罹患數。在政府支持和有希望的管道治療的幫助下,人們對這種疾病認知度擴大促進了市場的成長。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的花生過敏市場調查,總括性彙整市場概要,疾病概要和現行的治療方法,新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 主要洞察

第2章 花生過敏:市場概要

  • 花生過敏的市場佔有率(實際成果值)
  • 花生過敏的市場佔有率(預測值)

第3章 花生過敏:疾病背景和概要

  • 簡介
  • 花生過敏
    • 花生過敏的特徵
  • 臨床表現
    • 臨床症狀
  • 原因和風險因素
    • 危險因素
  • 花生過敏的病理生理學
  • 跟其他的食品的交叉反應性
  • 花生過敏的診斷
    • 診斷檢驗
    • 皮膚點刺試驗(SPT)
    • 血清花生IgE濃度
    • 成分檢驗
    • 花生誘發性過敏性反應反應

第4章 流行病學和患者人口

  • 主要調查結果

第5章 主要7個國家花生過敏的患病數

第6章 美國的流行病學

  • 假設和理論的根據
  • 整體患病數
  • 患病數:疾病類型
  • 患病數:各年齡
  • 患病數:病期(嚴重程度)

第7章 歐盟5國的流行病學

  • 德國
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)
  • 法國
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)
  • 義大利
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)
  • 西班牙
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)
  • 英國
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)
  • 日本
    • 假設和理論的根據
    • 整體患病數
    • 患病數:疾病類型
    • 患病數:各年齡
    • 患病數:病期(嚴重程度)

第8章 與治療流程現行治療

  • 一次預防
  • 管理
  • 口服免疫療法
  • 治療指南
    • 花生過敏的診療指南

第9章 未滿足需求

第10章 新藥

  • 關鍵交叉競爭
  • AR101:Aimmune Therapeutics
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Viaskin Peanut:DBV Technologies
  • ANB020:AnaptysBio
  • Omalizumab:Genentech

第11章 市場分析花生過敏:主要7個國家

  • 主要調查結果
  • 主要7個國家的市場規模

第12章 美國:市場預測

  • 美國的市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第13章 歐盟5國:市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 日本市場預測

  • 日本
    • 整體市場規模
    • 市場規模:各治療藥物

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

  • 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0160

DelveInsight's 'Peanut Allergy - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Peanut Allergy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Peanut Allergy from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Peanut Allergy - Disease Understanding

A peanut allergy is an allergic reaction to peanuts which occurs when the human body mistakenly identifies peanuts as harmful substances. Peanuts are not the same as tree nuts (almonds, cashews, walnuts, etc.), which grow on trees. In botanical terms, the peanut is not a nut, but a legume. It is one of the types of food that often provoke severe allergic reactions. In some cases, trace amounts of one milligram can trigger a reaction. In comparison, a peanut weighs between 500 and 1000 milligrams.

Peanut allergy is recognized as one of the most severe food allergies due to its prevalence, persistency, and the potential severity of the allergic reaction. Although other food allergies occurring in childhood usually resolve spontaneously with age, peanut sensitivity appears early in life and often persists indefinitely. Frequently, large quantities of peanut allergens are not needed to elicit an allergic reaction-even trace levels of peanut are capable of causing a hypersensitive reaction. Peanut allergy is estimated to affect 0.5-1.1% of the population, depending on the area studied.

Peanut-allergic individuals may experience symptoms ranging from mild urticaria, facial swelling, and abdominal cramp to hypertension with anaphylactic shock. In fact, it is the most common cause of fatal food-related anaphylaxis.

The DelveInsight Peanut Allergy market report gives a thorough understanding of the Peanut Allergy by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Peanut Allergy in the US, Europe, and Japan.

Peanut Allergy Epidemiology

The Peanut Allergy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by total prevalent population, age-specific prevalent population, gender-specific prevalent population and severity-specific prevalent population.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the prevalent population of Peanut Allergy was estimated to be 8,693,872 [7MM] in 2018. United States accounts for the highest Peanut Allergy cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among the EU5 countries France had the highest prevalent patient population of Peanut Allergy, followed by Germany.

Peanut Allergy Management

Currently, there is no standard of care for patients with Peanut Allergy, highlighting a pressing need to develop safe and effective curative interventions. The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. However all these therapies are used as off-label therapies and there is no approved therapy yet for the treatment of Peanut Allergy

The primary care of treatment, include antihistamines and injectible epinephrine, prescribed to patients with mild, and moderate to severe cases of Peanut Allergy. Antihistamines, known as H1 blockers, are beneficial for the treatment of acute mild reactions, (e.g., itching, sneezing, hives and rashes), although they cannot stop or control a severe reaction. Medications in this class include diphendydramine and cetirizine. Antihistamines do not treat anaphylaxis and have no life-saving capacity. Diphenhydramine has been commonly used as the antihistamine of choice for acute food allergic reactions given its prompt onset of action and ready availability, though epinephrine is still the first-line therapy for anaphylaxis. Cetirizine is a second generation antihistamine with a similar onset but longer duration of action (≥24 hours) compared to diphenhydramine. Furthermore, CNS effects are less commonly reported. Cetirizine has been used by patients in outpatient clinic for the treatment of acute allergic food reactions. In order to meet the high unmet need of Peanut Allergy treatment regimen, companies across the globe have shifted their focus towards this therapeutic area. Recent studies show promise in the effectiveness and safety of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). Additionally, improved diagnostic testing provides more accurate results while minimizing risk.

Peanut Allergy Market Outlook

The Peanut Allergy (PWS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Peanut Allergy (PWS) was estimated to be USD 3144.8 million in 2018. The United States accounts for the largest market size of Peanut Allergy, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.

Peanut Allergy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The overall dynamics of Peanut Allergy market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Aimmune Therapeutics' AR101, DBV Technologies' Viaskin Peanut, AnaptysBio's ANB020 and Genentech's Omalizumab. Out of these emerging therapies, AR101 (Aimmune Therapeutics) is expected to be launched in 2019 in the US. Aimmune's AR101 is expected to grab maximum market share, as it is currently in Phase III stage of clinical development with very good safety and eeficacy results, and will therefore influence the market size with a greater percentage. DBV Technologies's Viaskin Peanut, although would be launched later than AR101, i.e. in 2020, but still is expected to provide a significant competition in the therapeutic market.  

Peanut Allergy Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Peanut Allergy Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Peanut Allergy Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Peanut Allergy market.
  • Organize sales and marketing efforts by identifying the best opportunities for Peanut Allergy market.
  • To understand the future market competition in the Peanut Allergy market.

Table of Contents

1 Key Insights

2 Peanut Allergy: Market Overview at a Glance

  • 2.1 Total Market Share (%) Distribution of Peanut Allergy in 2016
  • 2.2 Total Market Share (%) Distribution of Peanut Allergy in 2027

3 Peanut Allergy: Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Peanut Allergans
    • 3.2.1 Characterization of Peanut Allergans
  • 3.3 Clinical Presentation
    • 3.3.1 Clinical Symptoms
  • 3.4 Causes and Risk Factors
    • 3.4.1 Risk Factors
  • 3.5 Pathophysiology of Peanut Allergy
  • 3.6 Cross-reactivity with Other Foods
    • 3.6.1 Outgrowing Peanut Allergy
  • 3.7 Diagnosis of Peanut Allergy
    • 3.7.1 History, the key Diagnostic Test
    • 3.7.2 Skin Prick Tests (SPT)
    • 3.7.3 Serum Peanut-IgE Concentration
    • 3.7.4 Component Testing
    • 3.7.5 Peanut-Induced Anaphylactic Reactions

4 Epidemiology and Patient Population

  • 4.1 Key Findings

5 Total Prevalent Population of Peanut Allergy in 7MM

6 United States Epidemiology

  • 6.1 Assumptions and Rationale
  • 6.2 Total Prevalent Population of Peanut Allergy in the United States
  • 6.3 Gender - Specific Prevalent Population of Peanut Allergy in the United States
  • 6.4 Age - Specific Prevalent Population of Peanut Allergy in the United States
  • 6.5 Severity - Specific Prevalent Population of Peanut Allergy in the United States

7 EU5 Epidemiology

  • 7.1 Germany Epidemiology
    • 7.1.1 Assumptions and Rationale
    • 7.1.2 Total Prevalent Population of Peanut Allergy in Germany
    • 7.1.3 Gender - Specific Prevalent Population of Peanut Allergy in Germany
    • 7.1.4 Age - Specific Prevalent Population of Peanut Allergy in Germany
    • 7.1.5 Severity - Specific Prevalent Population of Peanut Allergy in Germany
  • 7.2 France Epidemiology
    • 7.2.1 Assumptions and rationale
    • 7.2.2 Total Prevalent Population of Peanut Allergy in France
    • 7.2.3 Gender - Specific Prevalent Population of Peanut Allergy in France
    • 7.2.4 Age - Specific Prevalent Population of Peanut Allergy in France
    • 7.2.5 Severity - Specific Prevalent Population of Peanut Allergy in France
  • 7.3 Italy Epidemiology
    • 7.3.1 Assumptions and Rationale
    • 7.3.2 Total Prevalent Population of Peanut Allergy in Italy
    • 7.3.3 Gender - Specific Prevalent Population of Peanut Allergy in Italy
    • 7.3.4 Age - Specific Prevalent Population of Peanut Allergy in Italy
    • 7.3.5 Severity - Specific Prevalent Population of Peanut Allergy in Italy
  • 7.4 Spain Epidemiology
    • 7.4.1 Assumptions and Rationale
    • 7.4.2 Total Prevalent Population of Peanut Allergy in Spain
    • 7.4.3 Gender - Specific Prevalent Population of Peanut Allergy in Spain
    • 7.4.4 Age - Specific Prevalent Population of Peanut Allergy in Spain
    • 7.4.5 Severity - Specific Prevalent Population of Peanut Allergy in Spain
  • 7.5 United Kingdom Epidemiology
    • 7.5.1 Assumptions and Rationale
    • 7.5.2 Total Prevalent Population of Peanut Allergy in the United Kingdom
    • 7.5.3 Gender - Specific Prevalent Population of Peanut Allergy in the United Kingdom
    • 7.5.4 Age - Specific Prevalent Population of Peanut Allergy in the United Kingdom
    • 7.5.5 Severity - Specific Prevalent Population of Peanut Allergy in the United Kingdom
  • 7.6 Japan Epidemiology
    • 7.6.1 Assumptions and Rationale
    • 7.6.2 Total Prevalent Population of Peanut Allergy in the Japan
    • 7.6.3 Gender - Specific Prevalent Population of Peanut Allergy in the Japan
    • 7.6.4 Age - Specific Prevalent Population of Peanut Allergy in Japan
    • 7.6.5 Severity - Specific Prevalent Population of Peanut Allergy in the Japan

8 Treatment Algorithm, Current Treatment, and Medical Practices

  • 8.1 Primary Prevention
  • 8.2 Management
  • 8.3 Oral Immunotherapy
  • 8.4 Treatment Guidelines
    • 8.4.1 Practice Guidelines for Peanut Allergies

9 Unmet Needs

10 Emerging Therapies

  • 10.1 Key Cross Competition
  • 10.2 AR101: Aimmune Therapeutics
    • 10.2.1 Product Description
    • 10.2.2 Other Developmental Activities
    • 10.2.3 Clinical Development
    • 10.2.4 Safety and Efficacy
    • 10.2.5 Product Profile
  • 10.3 Viaskin Peanut: DBV Technologies
    • 10.3.1 Product Description
    • 10.3.2 Other Developmental Activities
    • 10.3.3 Clinical Development
    • 10.3.4 Safety and Efficacy
    • 10.3.5 Product Profile
  • 10.4 ANB020: AnaptysBio
    • 10.4.1 Drug Description
    • 10.4.2 Other Developmental Activities
    • 10.4.3 Clinical Development
    • 10.4.4 Safety and Efficacy
    • 10.4.5 Product Profile
  • 10.5 Omalizumab: Genentech
    • 10.5.1 Drug Description
    • 10.5.2 Other Developmental Activities
    • 10.5.3 Clinical Development
    • 10.5.4 Safety and Efficacy
    • 10.5.5 Product Profile

11 Peanut Allergy: 7MM Market Analysis

  • 11.1 Key Findings
  • 11.1 Market Size of Peanut Allergy in 7MM

12 United States: Market Outlook

  • 12.1 United States Market Size
    • 12.1.1 Total Market size of Peanut Allergy
    • 12.1.2 Market Size of Peanut Allergy by Therapies in the US

13 EU-5 countries: Market Outlook

  • 13.1 Germany Market Size
    • 13.1.1 Total Market size of Peanut Allergy
    • 13.1.2 Market Size of Peanut Allergy by therapies in Germany
  • 13.2 France Market Size
    • 13.2.1 Total Market size of Peanut Allergy
    • 13.2.2 Market Size of Peanut Allergy by therapies in France
  • 13.3 Italy Market Size
    • 13.3.1 Total Market size of Peanut Allergy
    • 13.3.2 Market Size of Peanut Allergy by therapies in Italy
  • 13.4 Spain Market Size
    • 13.4.1 Total Market size of Peanut Allergy
    • 13.4.2 Market Size of Peanut Allergy by therapies in Spain
  • 13.5 United Kingdom Market Size
    • 13.5.1 Total Market size of Peanut Allergy
    • 13.5.2 Market Size of Peanut Allergy by therapies in the UK

14 Japan Market Outlook

  • 14.1 Japan Market Size
    • 14.1.1 Total Market size of Peanut Allergy
    • 14.1.2 Market Size of Peanut Allergy by therapies in Japan

15 Market Drivers

16 Market Barriers

17 Appendix

  • 17.1 Report Methodology

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

List of Tables

  • Table 1: Characteristics of Peanut Allergens
  • Table 2: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
  • Table 3: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
  • Table 4: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Table 5: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Table 6: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Table 7: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
  • Table 8: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
  • Table 9: Age-Specific Prevalence of Peanut Allergy in the Germany (2016-2027)
  • Table 10: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
  • Table 11: Total Prevalent Population of Peanut Allergy in France (2016-2027)
  • Table 12: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Table 13: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Table 14: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Table 15: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
  • Table 16: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Table 17: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Table 18: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Table 19: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
  • Table 20: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Table 21: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Table 22: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Table 23: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
  • Table 24: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Table 25: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Table 26: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Table 27: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
  • Table 28: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
  • Table 29: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
  • Table 30: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
  • Table 31: Emerging Drugs Analysis
  • Table 32: Emerging Drugs Analysis - Continued
  • Table 33: AR101, Clinical Trial Description, 2018
  • Table 34: Viaskin Peanut, Clinical Trial Description, 2018
  • Table 35: ANB020, Clinical Trial Description, 2018
  • Table 36: Omalizumab, Clinical Trial Description, 2018
  • Table 37: Market Size of Peanut Allergy in 7MM in USD Million (2016-2027)
  • Table 38: The US Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 39: Market Size of Peanut Allergy by therapies in the US in USD Million (2016-2027)
  • Table 40: Germany Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 41: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
  • Table 42: France Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 43: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
  • Table 44: Italy Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 45: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
  • Table 46: Spain Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 47: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
  • Table 48: The UK Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 49: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
  • Table 50: Japan Market Size of Peanut Allergy in USD Million (2016-2027)
  • Table 51:Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)

List of Figures

  • Figure 1: Clinical Symptoms of Peanut Allergy
  • Figure 2: Peanut Allergy Risk Factors
  • Figure 3: Peanut activation of complement exacerbates anaphylaxis
  • Figure 4: Total Prevalent Population of Peanut Allergy in the 7MM (2016-2027)
  • Figure 5: Total Prevalent Population of Peanut Allergy in the US (2016-2027)
  • Figure 6: Gender Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Figure 7: Age-Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Figure 8: Severity Specific Prevalence of Peanut Allergy in the US (2016-2027)
  • Figure 9: Total Prevalent Population of Peanut Allergy in Germany (2016-2027)
  • Figure 10: Gender Specific Prevalence of Peanut Allergy in Germany (2016-2027)
  • Figure 11: Age-Specific Prevalence of Peanut Allergy in Germany (2016-2027)
  • Figure 12: Severity Specific Prevalence of Peanut Allergy in Germany (2016-2027)
  • Figure 13: Total Prevalent Population of Peanut Allergy in France (2016-2027)
  • Figure 14: Gender Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Figure 15: Age-Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Figure 16: Severity Specific Prevalence of Peanut Allergy in France (2016-2027)
  • Figure 17: Total Prevalent Population of Peanut Allergy in Italy (2016-2027)
  • Figure 18: Gender Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Figure 19: Age-Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Figure 20: Severity Specific Prevalence of Peanut Allergy in Italy (2016-2027)
  • Figure 21: Total Prevalent Population of Peanut Allergy in Spain (2016-2027)
  • Figure 22: Gender Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Figure 23: Age-Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Figure 24: Severity Specific Prevalence of Peanut Allergy in Spain (2016-2027)
  • Figure 25: Total Prevalent Population of Peanut Allergy in the UK (2016-2027)
  • Figure 26: Gender Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Figure 27: Age-Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Figure 28: Severity Specific Prevalence of Peanut Allergy in the UK (2016-2027)
  • Figure 29: Total Prevalent Population of Peanut Allergy in Japan (2016-2027)
  • Figure 30: Gender Specific Prevalence of Peanut Allergy in Japan (2016-2027)
  • Figure 31: Age-Specific Prevalence of Peanut Allergy in Japan (2016-2027)
  • Figure 32: Severity Specific Prevalence of Peanut Allergy in the Japan (2016-2027)
  • Figure 33: Algorithm for Peanut Allergy treatment
  • Figure 34: Unmet Needs of Peanut Allergy
  • Figure 35: Market Size of Peanut Allergy in the 7MM in USD Million (2016-2027)
  • Figure 36: Market Size of Peanut Allergy in the US, USD Millions (2016-2027)
  • Figure 37: Market Size of Peanut Allergy by therapies in the United States in USD Million (2016-2027)
  • Figure 38: Market Size of Peanut Allergy in Germany, USD Millions (2016-2027)
  • Figure 39: Market Size of Peanut Allergy by therapies in Germany in USD Million (2016-2027)
  • Figure 40: Market Size of Peanut Allergy in France, USD Millions (2016-2027)
  • Figure 41: Market Size of Peanut Allergy by therapies in France in USD Million (2016-2027)
  • Figure 42: Market Size of Peanut Allergy in Italy, USD Millions (2016-2027)
  • Figure 43: Market Size of Peanut Allergy by therapies in Italy in USD Million (2016-2027)
  • Figure 44: Market Size of Peanut Allergy in Spain, USD Millions (2016-2027)
  • Figure 45: Market Size of Peanut Allergy by therapies in Spain in USD Million (2016-2027)
  • Figure 46: Market Size of Peanut Allergy in the UK, USD Millions (2016-2027)
  • Figure 47: Market Size of Peanut Allergy by therapies in the UK in USD Million (2016-2027)
  • Figure 48: Market Size of Peanut Allergy in the Japan, USD Millions (2016-2027)
  • Figure 49: Market Size of Peanut Allergy by therapies in Japan in USD Million (2016-2027)
  • Figure 50: Market Drivers
  • Figure 51:Market Barriers